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Abstract.  Vascular cell adhesion molecule  1 
(VCAM-1), a  member of the Ig superfamily originally 
identified on activated endothelium, binds to the inte- 
grin very late antigen-4 (VLA-4), also known as ot4~l 
or CD49d/CD29,  to support cell-cell adhesion. 
Studies based on cell adhesion to two alternatively 
spliced forms of VCAM-1  or to chimeric molecules 
generated from them and intercellular adhesion 
molecule-1  (ICAM-1) have demonstrated two VLA-4 
binding sites on the predominate form of VCAM-1. 
Here, we studied VLA-4-dependent adhesion of the 
lymphoid tumor cell line Ramos to cells expressing 
wild type and mutant forms of VCAM-1.  Results based 
on domain deletion mutants demonstrated the exis- 
tence and independence of two VLA-4-binding sites 
located in the first and fourth domains of VCAM-1. 
Results based on amino acid substitution mutants 
demonstrated that residues within a  linear sequence of 
six amino acids found in both domain 1 and 4  were 
required for VLA-4 binding to either domain. Five of 
these amino acids represent a  conserved motif also 
found in ICAM domains. We propose that integrin 
binding to these Ig-like domains depends on residues 
within this conserved motif. Specificity of integrin 
binding to Ig-like domains may be regulated by a  set 
of nonconserved residues distinct from the conserved 
motif. 
T 
H~  binding  of vascular  cell  adhesion  molecule  1 
(VCAM-1) L  to very late antigen-4 (VLA-4) (a4#t) has 
been implicated in numerous physiologic and patho- 
physiologic processes involving cell-cell adhesion (51). On 
activated endothelium, VCAM-1 supports the adhesion of 
lymphocytes (7, 15, 36, 42, 47), monocytes (6), eosinophils 
(4, 14, 62), basophils (4), natural killer cells (1), and certain 
tumor cells, particularly malignant melanoma and osteosar- 
coma (19, 27, 51, 56).  Adhesion of VLA-4-expressing cells 
to endothelium has been implicated in the pathogenesis of 
many diseases and disease processes, including rheumatoid 
arthritis (24,  30, 40, 57), osteoarthritis (24,  30), allogeneic 
graft rejection (5, 38), graft-versus-host disease (33-35), en- 
cephalomyelitis (2, 65), delayed-type hypersensitivity reac- 
tions (32), tumor metastasis (19, 27, 41, 56), and atherogene- 
sis  (9).  VCAM-1 has also been identified on a  variety of 
nonvascular cell types, including follicular dendritic cells 
(17, 26), bone marrow stromal cells (29, 45, 48), secondary 
myoblasts (44), some macrophages (43), certain renal epi- 
thelial cells (43), fibroblast-like synoviocytes (28, 30), reac- 
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tive mesothelial cells (23,  43),  stimulated astrocytes (22), 
and stimulated cortical neurons (3).  Roles for VCAM-1 in 
germinal center development (17), lymphopoiesis (29, 45, 
48), and myogenesis (44) have been suggested. 
Alternative splicing of  mRNA from a single VCAM-1 gene 
can produce two forms of VCAM-1 (8, 21, 39): a form con- 
taining seven Ig-like domains (VCAM-7D) and a form con- 
taining six Ig-like domains (VCAM-6D).  The two forms of 
VCAM-1 are identical in amino acid sequence except for the 
absence in VCAM-6D  of domain 4  (8,  21,  36,  39).  Both 
forms of  VCAM-1 have been isolated as eDNA from libraries 
prepared from stimulated endothelial cells, and as expressed 
in  transfected cell lines,  both  support  VLA-4-dependent 
adhesion (21, 59).  mRNA for both VCAM-6D and VCAM- 
7D has been identified in cultured endothelial cells (8, 21, 
28), synovial fibroblasts (28), and mesothelial cells (23), al- 
though  VCAM-7D  mRNA  predominates  particularly  in 
chronically  stimulated  cells.  At  the  protein  level,  only 
VCAM-7D has been identified on endothelial cells and syno- 
vial fibroblasts stimulated for 24 h with TNF (8, 28); how- 
ever, after 2 h of stimulation of synovial fibroblasts, a glyco- 
protein with an apparent molecular weight 10-15  kD less 
than  VCAM-7D  has  been  clearly  identified (28).  In  the 
mouse, a three-domain, glyeophosphatidylinositol-anchored 
form of VCAM-1 has been identified in addition to VCAM- 
7D (66; and Kinashi, T., Y. St. Pierre, C.-H. Huang, and T. 
A. Springer, manuscript submitted for publication). 
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two distinct sites. Based on the ability of anti-VCAM-1  mAb 
to inhibit lymphocyte adhesion to VCAM-TD versus VCAM- 
6D transfectants, we have concluded that one VLA-4 binding 
site is shared between VCAM-7D and VCAM-6D, whereas 
a second binding site localizes to the alternatively spliced do- 
main 4 (59). The high degree of sequence homology between 
domain 1 and domain 4  suggested that the shared VLA-4 
binding site localizes to domain 1. Based on lymphoid cell 
adhesion to chimeric constructs generated from VCAM-7D 
or VCAM-6D and intercellular adhesion molecule-I (ICAM- 
1), Osborn et al. (37) has concluded that VLA-4 binds dis- 
tinctly to domains 1 and 4. 
Here  we  have  characterized  VLA-4  binding  sites  in 
VCAM-1 based on domain deletion and amino acid substitu- 
tion mutants, similar to the strategy previously used to iden- 
tify binding sites in ICAM-1 for its integrin receptors LFA-I 
(52) and Mac-1 (13). In a first series of experiments, domain 
1 deletion mutants of both VCAM-7D and VCAM-6D were 
analyzed for expression and lymphoid cell binding, and com- 
pared to wild-type forms. The domain specificities of several 
anti-VCAM-1  mAb were determined and compared to the 
ability of the mAb to inhibit cell binding. In a second series 
of experiments, amino acid substitution mutations were tar- 
geted to domains 1 and 4, and analyzed for binding to VLA- 
4-expressing cells. Our results not only demonstrate inde- 
pendent VLA-4 binding sites in domain 1 and domain 4 of 
VCAM-7D,  but also demonstrate a critical binding function 
for residues within a six-amino acid sequence found in do- 
main 1 and domain 4. Five of these represent a conserved 
motif also found in ICAM domains. 
Materials and Methods 
Cell Culture 
The VLA-4-expressing human  B lymphoblastoid  cell line Ramos and SV-40 
transformed African green monkey kidney cells (COS) were maintained in 
RPMI 1640 with 10% FCS,  5 mM glutamine, and 50 izg/ml gentamicin. 
Human umbilical vein endothelial cells (HUVEC) were maintained as pre- 
viously described (59). 
Antibodies 
The mouse anti-VCAM-1 mAbs HAE-2a,  HAE-2b,  HAE-2c,  HAE-2d, 
HAE-2j, and HAE-2f were generated following  immunization of female 
BALB/c mice with HUVEC stimulated for 6 h with TNF, according to pre- 
viously described methods (50).  Hybridomas were screened by testing tis- 
sue culture supernatant for reactivity with  purified VCAM-7D. Other mouse 
anti-VCAM-1 mAb used were 1.4C3 (63) and 4B9 (7). All mAb used were 
isotype IgG1. mAb were used as neat tissue culture supernatant (HAE-2b, 
HAE-2c,  HAE-2d, HAE-2j, and HAE-2f), as a  1:500 dilution of ascites 
(HAE-2a), or as 20 ~tg/ml of purified protein (1.4C3 and 4B9). The mouse 
anti-human VLA-4 mAb HP2/1 (46) was used as 40 ~tg/ml of purified pro- 
tein (AMAC Corp., Westbrook,  ME). 
Generation of VCAM-1 Mutants 
Ollgonucleotide-directed  mutagenesis  was used to generate VCAM-I do- 
main deletion and amino acid substitution mutants, according to methods 
previously described (52). Domain deletion mutations were made using sin- 
gle strand templates  containing the VCAM 7D cDNA clone 1Ell or the 
VCAM-6D cDNA clone 41 in the expression vector CDM8. Domain dele- 
tions were guided by previous assignment of VCAM-1 domain boundaries 
(36). Amino acid substitution mutants were made using single strand tem- 
plates of VCAM-6D  or VCAM 7D/DI-,  a domain 1 deletion mutant of 
W.AM-7D. Following second-strand synthesis and transformation  in Esche- 
richia coil, mutants were isolated by screening for unique restriction sites 
conferred  by mutant oligonucleotides.  DNA sequencing confirmed each 
mutation. 
Generation of  a VCAM-I Domain 4~Human IgG 
Chimeric Molecule 
A  chimera containing VCAM-1 domain 4  fused to human IgGt  hinge, 
CH2, and CH3 was generated according to methods previously  described 
(55). Using W.AM-7D cDNA and the ollgonucleotide  primers 5°TTTACT  - 
GTTGAGATCTCCCCT and 5'TTTCTCGAGTCTCACCTGAGTAGAU~T- 
CCACCTGGAT, a polymerase chain reaction product containing domain 4 
sequence  was  generated, digested  with restriction enzymes HindIII and 
XhoI, and then ligeted  to the expression vector pCDGI  (55).  This con- 
struct, pCDVC-D4/IgG,  was transfected into COS cells, and a soluble chi- 
mera containing a dimer of VCAM-1 domain 4 fined to hinge,  CH2, and 
CH3 of IgG1 (VC-D4/IgG)  was purified from tissue culture supernatant by 
protein A-Sepharose chromatography. 
Transfected COS Celi Adhesion Assay 
COS cells were transfected  with purified plnsmid and prepared for assay 
three days later, as previously  described (59).  Transfected COS cells were 
washed three times with 1% FBS/RPMI at 25°C, and in some cases, pre- 
incubated for 15 min with anti-W.AM-1  mAb. Ramos cells were labeled 
as described (59) with the carboxyltuorescein  compound BCECF-AM (Bio- 
probes,  Eugene,  OR), resuspended in 1% FBS/RPMI, and in soma cases, 
preincubated with the anti-VLA-4 mAb HP2/I for 15 rain at 25°C.  Ramos 
cells were added to 60 mm×  15 mm tissue culture dishes (4 ×  106/dish) 
for 10 min at 25°C.  Nonadherem cells were removed by five washes using 
1% FBS/RPMI, and dishes were fixed with 2% paraformaldehyde  in PBS. 
Figure  1.  Schematic representation of VCAM-6D and VCAM-7D. 
Immunoglobulin-like domains are numbered D1-D7  with DI  lo- 
cated amino-termlnal and most distal from membrane. V~AM-6D 
primary structure differs from VCAM-7D by the absence of I)4. 
Sites of potential N-linked glycosylation are indicated by o. 
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1.4C3  HAE-2f  HAE-2a  HAE-2b  HAE-2c  4B9  HAE-2d  HAE-2j 
A. Wild-type  and domain 1 deletion  mutants* 
Mean linear fluorescence 
(%  1.4C3 binding to VCAM-7D 5: SE, N =  2-7) 
7D  100  103 5:5  81  5:9  86 5:13  99  5:18  102 5:11  62 +  12  83 5:11 
6D  92 5:15  78 5=  17  60 5:2  62 5:6  74 5:13  58 5:6  ~ 
7D/D1-  1365:14  112+29  ['----ff-~-~  ~  ~  ~  1335:24  895:4 
6D/DI-  33 5:6  36 5:9  ]  3+2[  I  25:2  I  [  0±0  I  I  05:0  I  ~ 
B. Domain 1 amino  acid substitution  mutants  of VCAM-6D 
Mean linear fluorescence 
(%  1.4C3 binding to VCAM-7D +  SE, N =  2-7) 
E29/A  63 5:10  51  +  6  61  +  1  61  5:1  64 +  10  66 5:10  0 5:0  5 +  4 
R36/G  50 5:10  90 -l- 4  38 +  14  50 +  3  48 5:6  53 +  14  8 +  8  20 +  10 
Q38/S  105 +  19  77 +  1  64 5:20  95  +  19  82 +  14  80 +  8  4 5:4  21  5:9 
D40/A  52 5-  1  57 5:2  55 5:4  62 +  2  57 5:0  ND  0  +  0  0  -I- 0 
L43N/AD  66 5:10  69 5:13  42  +  14  58 5:12  55 +  13  ~  13 +  7  22 +  9 
E76/A  67 5:8  64 ±  14  46  +  12  66 +  12  59 5:7  57 5:9  9 5:7  22 5:9 
R78K/QA  59 +4  69 +2  78 +  16  ~  53  +  1  ~  2  5:1  1 +  1 
50% VCAM-6D*  30 
C. Domain  4 amino  acid substitution  mutants  of VCAM-7D/D1- 
31  37  29 
Mean linear fluorescence 
(%  1.4423 binding to VCAM-7D  5: SE, N  =  1-3) 
E317/A  146 +  2  106 +  23  4  5:3  12 +  1  14 5:2  4  +  3  84 5:28  168 +  25 
D328/A  106 5: 17  98 5:24  0  +  0  9 5:4  10 5: 1  0  180 +  17  157 -i- 33 
L331/A  101  +  3  109 +  17  1 5:1  1 +  1  3 +  1  5 +  4  92 5:24  111  5:18 
K366K/QA  132 +  24  138 +  14  3 5:2  5 ±  4  11  5:0  3 +  3  97  +  25  80 5:23 
50% VCAM-7D/DI-*  67  45 
* In A boxes indicate  fluorescence  values that are less than 50% of that obtained  using 1.4123 and the corresponding  VCAM construct. 
* In B and C boxes indicate  fluorescence  values less than 50% of that obtained  using  the same mAb and COS-expressing  VCAM-tD(B) or VCAM-7D/DI-(C). 
For each experiment,  bound  Ramos cells were quantified  using  a fluores- 
cence microscope  to score the number  of ceils in three to five 100× fields. 
Phase contrast  was used  to count  the number  of  COS cells in  the same fields. 
COS ceil transfectants  were also labeled  with a panel of anti-VCAM-1  mAb 
for flow cytometry as described (12). Transfection  efficiency was deter- 
mined as the percentage of tmnsfect~ cells labeled by the anti-WAM-1 
mAb 1.4C3 subtracted  by the percentage of mock transfected ceils labeled 
by 1.4C3. Binding  of Ramos cells was quantified  as ceils bouncFtransfected 
COS cells --- ([ceils  bound to VCAM-l-transfectants/mm  2] -  [ceils bound 
to mock transfectants/mm2])/([COS  ceils/ram  2]  ×  [VCAM-I transfecfion 
efficiency])  and expressed as percentage  of  binding  to wild-type  ~.AM-7D. 
Results 
Generation and Expression of  Domain 1 Deletion 
VCAM-1 Mutants 
The amino-terminal  Ig-like domains (D]) of VCAM-6D and 
VCAM-7D  (Fig.  1)  were  deleted  using  oligunucleotide- 
directed mutagenesis. Expression of each mutant and wild- 
type  form  in  COS  cells  was  determined  using  eight 
anti-VCAM-1 mAb. Two mAb, 1.4C3 and HAE-2f, recog- 
nized each of the wild-type and domain 1 deletion mutants. 
As indicated by the mean linear fluorescence intensity of 
cells labeled by these rnAb (Table I A), expression of VCAM- 
7D, VCAM-6D, and the VCAM-7D domain 1 deletion mu- 
tant, VCAM-7D/DI-, was  comparable.  Expression of the 
VCAM-6D domain 1 deletion mutant, VCAM-6D/DI-, was 
about 65 %  less than that of VCAM-7D. 
Four anti-VCAM-1 mAb (HAE-2a,  HAE-2b,  HAE-2c, 
and 4B9)  recognized VCAM-7D and VCAM-6D transfec- 
rants with a mean linear fluorescence comparable to that of 
mAb 1.4C3 and HAE-2f (Table I A). None of these mAb rec- 
ognized  VCAM-6D/D1-  or  VCAM-7D/D1-  transfectants, 
and therefore represent a group of anti-VCAM-I mAb whose 
epitopes depend on domain 1. 
Two other anti-VCAM-1 mAb (HAE-2d and HAE-2j) rec- 
ognized VCAM-7D  and VCAM-7D/D1- transfectants, but 
failed to bind (HAE-2d) or weakly bound (HAE-2j) VCAM- 
6D transfectants (Table I A).  Neither HAE-2d or HAE-2j 
recognized  VCAM-6D/D1-  transfectants,  and  thus  these 
mAb represent a group of mAb whose epitopes depend pri- 
marily on domain 4. 
Anti-VCAM-1 mAb Reactivity for the 
Chimera VC-D41IgG 
Based on ELISA, three of eight anti-VCAM-1 mAb (HAE- 
2b,  HAE-2d, and HAE-2j) were found to react with VC- 
D4/IgG, a chimeric protein consisting of VCAM-1 domain 
4 fused to hinge and constant regions of human IgG (Fig. 2). 
For HAE-2d and HAE-2j, this result was consistent with 
their labeling of VCAM-7D and VCAM-TD/D1- transfec- 
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1.4C3  HAE-2f  HAE-2a HAE-2b  HAE-2c  4B9  HAE.2d  H.AE-2j  R6.5 
Figure 2. Binding of eight anti-VCAM-1 mAb and the anti-ICAM-1 
rnAb R6.5 to VC-IM/IgG  (solid  bars)  or IC-D2/IgG (hatched  bars). 
Binding is shown as absorbance based on ELISA from a representa- 
tive of three experiments. Error bars represent  1 SD for duplicate 
results. 
tants  (Table I  A).  HAE-2b  reacted  with  VC-D4/IgG but 
failed  to  recognize  domain  4  as  expressed  by  VCAM- 
7D/D1- transfectants. As a control, none of the anti-VCAM- 
1 mAb were shown to react with the ICAM-1 chimera IC- 
D2/IgG (55),  although the anti-ICAM-1 mAb R6.5 bound 
well to IC-D2/IgG. 
VLA-4-dependent Adhesion to Domain 1 
Deletion Mutants 
To characterize the contributions of domain 1 and domain 4 
in the binding of VCAM-1 to VLA-4, adhesion of the B lym- 
phoblastoid cell line Ramos to COS cells expressing either 
mutant or wild-type forms of VCAM-1  was assessed. Bind- 
ing was quantified relative to Ramos cell binding to VCAM- 
7D transfectants (Fig.  3). Ramos cells bound well to COS 
cells expressing VCAM-7D or VCAM-6D, forming rosettes 
of 10-20 Ramos cells on average per transfected COS cell. 
Ramos  cells  also  bound  to  COS  cells  transfected  with 
VCAM-7D/D1- but only ,~60%  as well as they bound to 
VCAM-7D. In contrast, there was no binding of Ramos cells 
to VCAM-6D/D1-.  These findings  suggest that domains  1 
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Figure 3. Ramos cell binding to COS cells expressing VCAM-7D, 
VCAM-6D,  VCAM-7D/DI-,  or  VCAM-6D/D1-.  Binding was 
quantified relative to the binding to VCAM-7D. Error bars repre- 








HAE-2a  HAE-2b  HAE-2c  4B9  HAE-2d  HA~2j  14C3  HP211 
HAE-2a HAE-2b HAE-2c  4II9  HAE-2d HAE-2j  1.4C3  HP2/I 
7D/D1 - 
HAE-2a  HAE-2b  HAE-2c  4B9  HAE-XI  HAE-2j  1,4C3  llP2/l 
Figure 4. Ramos cell binding to COS cells expressing VCAM-TD 
(7D), VCAM-6D (6D), or VCAM-7D/D1- (7D/D1-) in the pres- 
ence of anti-VCAM-1 mAb or the anti-VLA-4 mAb HP2/1. Binding 
was quantified relative to the binding to VCAM-7D in the presence 
of control medium. Error bars represent  1 SD for two to three ex- 
periments. Experiments with VCAM-7D/D1- using mAb 4B9 and 
HP2/1 were done once. 
Seven anti-VCAM-1 mAb were examined for their abilities 
to inhibit Ramos cell binding to VCAM-7D, VCAM-6D, or 
VCAM-7D/D1-  COS  cell transfectants  (Fig.  4).  The four 
domain  1-dependent mAb completely blocked Ramos cell 
binding to both VCAM-7D and VCAM-6D, whereas none of 
mAb bound  well to COS cells expressing VCAM-7D/D1- 
(Table I A),  and consequently,  none  inhibited  Ramos cell 
binding to VCAM-7D/D1-.  Two domain 4-dependent rnAb 
blocked Ramos cell binding to VCAM-TD/D1- but did not 
block binding  to  VCAM-7D  or  VCAM-6D.  mAb  1.4C3, 
whose epitope was independent of both domains  1 and 4, 
failed  to  inhibit  binding  to  VCAM-7D,  VCAM-6D,  or 
VCAM-7D/DI-,  The anti-VCAM-1  mAb HAE-2f was not 
tested. As a control, the anti-VLA-4 mAb HP2/1 was shown 
to  block  Ramos  cell  binding  to  any  VCAM-l-expressing 
transfectant.  The domain specificity and function-blocking 
patterns of these mAb provide further evidence for indepen- 
dent  VLA-4 binding  sites  in  domain  1 and  domain 4  of 
VCAM-1. 
Generation of VCAM-1 Amino Acid 
Substitution Mutants 
VLA-4 binding  sites  were further characterized based on 
amino acid substitution mutants of VCAM-6D and VCAM- 
7D/D1- generated by oligonucleotide-directed mutagenesis. 
Based  on  the  functional  as  well  as  predicted  structural 
similarities between domain 1 of ICAM-1 and domains 1 and 
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acids in VCAM-1 analogous to amino acids in ICAM4 found 
to be critical for binding to LFA-1 (Fig. 5; see reference 52). 
Domain 1 mutations were made in VCAM-6D, and domain 
4 mutations were made in VCAM-7D/D1-.  Additional mu- 
tations were made in domain 1 of VCAM-6D in a region of 
four amino acids (W-R-T-Q) that lacks a structural analog in 
ICAM-1 (Fig. 5). Notation for the mutations uses the one- 
letter code for the wild-type sequence followed  by a slash and 
the one-letter code for the corresponding mutant sequence; 
the position of the first amino acid is indicated relative to the 
predicted NH2-terminal phenylalanine residue of VCAM-7D. 
Expression and VI~-4-dependent Adhesion to 
Domain 1 Amino Acid Substitution Mutants 
Seven substitution mutants of one to two amino acids were 
made in domain 1 of VCAM-6D. Expression of each mutant 
in COS cells was comparable to that of  the wild-type VCAM- 
6D, as determined by flow cytometry using two mAb, 1.4C3 
and HAE-2f, for which the epitopes did not depend on do- 
mains 1 or 4 (Table I B). The conformational integrity of do- 
main 1 was confirmed for seven mutants by the binding of 
at least two out of four domain 1-dependent mAb. mAb were 
considered to bind a mutant well if the mean linear fluores- 
cence of the mAb labeling COS cells expressing the mutant 
was not less than 50%  of the mean linear fluorescence of 
the same mAb labeling  COS cells expressing VCAM-6D. 
The mAb 4B9 poorly recognized mutants  L43N/AD  and 
R78K/QA. The mAb HAE-2a marginally recognized mutant 
R36/G. Mutant MSK/QA was not recognized by mAb HAE- 
2b (Table I B). 
Three  domain  1  mutants-Q38/S,  D40/A,  and  IM3N/ 
AD-failed to support Ramos cell adhesion despite good ex- 
pression and intact conformation of domain  1 (Fig.  6 A). 
Binding to four other domain  1 mutants-E29/A,  R36/G, 
E76/A, and R78K/QA-was comparable to that observed to 
wild-type VCAM-6D. 
Expression and VLA-4-dependent Adhesion to 
Domain 4 Amino Acid Substitution Mutants 
Substitution mutants analogous to four of those generated in 
domain 1 of VCAM-6D were made in domain 4 of VCAM- 
7D/D1-.  Expression  after  transfection  was  shown  using 
four  anti-VCAM-1  mAb  that  recognized VCAM-7D/DI-, 
and conformational integrity was confirmed by the binding 
of two mAb whose epitopes depended primarily on domain 
4  (Table I  C).  None of these mutants were recognized by 
mAb whose epitopes depended on domain 1. 
Ramos  cells failed to bind to the mutants  D328/A and 
L331/A  (Fig.  6  B)  but did bind to  mutants  E317/A  and 
K366K/QA as  well as they did to VCAM-7D/D1-.  Thus, 
amino acids homologous to those found to be critical in the 
binding of domain 1 to VLA-4 were also found to be critical 
in the binding of domain 4  to VLA-4. 
Discussion 
The binding  of the integrin VLA-4  (c~4/31) to VCAM-1,  a 
member of the Ig superfamily with two alternatively spliced 
forms, plays an important role in mediating chronic inflam- 
marion and numerous other physiologic processes involving 
cell-cell adhesion. In the present study, we examined cell 
adhesion to mutant forms of VCAM-1 in order to determine 
the  molecular basis  of VLA-4  binding  to  VCAM4.  Our 
findings not only demonstrate two independent VLA-4 bind- 
ing sites in domains 1 and 4 but also identify a critical bind- 
ing function for amino acids within the linear sequence Q-I- 
D-S-P-L, which is identically expressed in the two domains. 
Consistent with previous observations (37, 59), the exis- 
tence and independence of two VLA-4 binding sites in do- 
mains  1 and 4  were clearly demonstrated by Ramos  cell 
binding to domain 1 deletion mutants of VCAM-1.  Ramos 
cells bound well to VCAM-TD, VCAM-6D, and VCAM-TD/ 
D1- but not to  VCAM-6D/D1-.  Neither domain  1-depen- 
'7, 
6D  E29/A R36/G  Q38/S  D40/A  [A3N/AD E76/A R78K/QA 
Figure 5.  Amino acid sequence alignmem of ICAM-1 domain 1, 
VCAM-1 domain 1, and VCAM-1 domain 4. Mutation of single or 
groups of amino acids in ICAM-1 domain 1 that significantly de- 
creased LFA-1 binding (52) are boxed. Amino acids in domains 1 
and 4 of VCAM-1 that were targeted for mutation in these experi- 
ments are underlined. 
7DtDI-  E317/A  D328/A  L33|/A  K366K/QA 
Figure 6.  Ramos cell binding to COS ceils expressing VCAM-1 
amino  acid  substitution  mutants  targeted  to  (A)  domain  1 of 
VCAM-6D or (B) domain 4 of VCAM-TD/DI- is shown relative 
to Ramos cell binding to VCAM-7D. Error bars represent 1 SD for 
two to three experiments. 
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ous expression of domain 4,  nor did domain 4-dependent 
adhesion (to VCAM-TD/D1-)  require expression of domain 
1. In addition, the ability of  anti-VCAM-1 mAb to inhibit do- 
main  1- or domain 4-dependent adhesion correlated with 
their domain speeificities: mAb whose epitopes depended on 
domain 1 blocked Ramos cell binding to VCAM-6D but not 
VCAM-7D/DI-,  and mAb  whose epitopes  depended pri- 
marily on domain 4 blocked Ramos cell binding to VCAM- 
7D/D1- but not VCAM-6D.  The domain 1-dependent mAb 
tested here also completely blocked binding to VCAM-7D. 
The biological significance of two VLA-4 binding sites on 
VCAM-7D versus one VLA-4 binding site on VCAM-6D re- 
mains unclear. Although under most (but not all [28]) exper- 
imental systems, VCAM-7D expression appears to dominate 
VCAM-6D expression, a three-domain, glycophosphatidyl- 
inositol-anchored form of murine VCAM-1 has been identi- 
fied in the mouse, apparently with one VLA-4 binding site 
(66; and Kinashi, T., Y. St. Pierre, C.-H. Huang, and T. A. 
Springer, manuscript submitted for publication). If it is pos- 
sible for two VLA-4 molecules to bind simultaneously to 
VCAM-7D (as size considerations suggest it should be) (51), 
then bivalent versus monovalent binding may help regulate 
strength of adhesiveness as well as differential signals trans- 
mitted to VLA-4-expressing cells upon ligation. 
Amino  acid  substitution  mutants  of  VCAM-6D  and 
VCAM-7D/D1-  defined binding sites in domains 1 and 4, 
respectively. Three mutations in domain 1 eliminated bind- 
ing: Q38/S,  D40/A, and L43N/AD. In domain 4 of VCAM- 
7D/DI-, two mutations were made in amino acids analogous 
to those required for VLA-4 binding to domain 1-D328/A 
and L331/A-and both eliminated binding of VLA-4 to do- 
main 4.  Thus,  VLA-4-binding sites  in domains  1 and 4 
minimally involve amino acids within a linear sequence of 
six amino acids that is identical in both domains: Q~s-I~9- 
D4o-S41-P42-l-43 in domain 1 and Q326-I327-D328-S329-P330-L331  in 
domain 4. 
The first domain of human ICAM-1  conservatively ex- 
presses the five COOH-terminal amino acids of this linear 
sequence; namely, I33-E34-T35-P36-L37 (Fig. 7). Furthermore, 
mutation of E~ of ICAM-1, which is homologous to D4o of 
domain  1 of VCAM-1 and to D32a of domain 4  (Fig.  7), 
eliminates binding of ICAM-1 to its integrin receptor LFA-1 
(52).  In addition, human ICAM-2 and ICAM-3, which also 
bind integrins (11, 53), express five amino acid motifs ho- 
mologous to the VCAM-1 and ICAM-1 motif  except for a ser- 
ine residue substituted for proline at the fourth position. Mu- 
rine  ICAM-1,  ICAM-2,  and  VCAM-1 express  a  motif 
homologous to the human VCAM-1 and ICAM-1 motif ex- 
cept for one or two other nonconserved substitutions (Fig. 
7). For each human and murine Ig domain noted in Fig. 7, 
the motif is predicted to be found on the turn between/~ 
sheets C and D. 
Based on these functional and predicted structural similar- 
ities  of VCAM-1 and  ICAM  domains,  we  propose  that 
residues with the conserved motif  I(L)-D(E)-S(T)-P(or S)-L 
are necessary but insufficient for integrin binding. A set of 
nonconserved amino acids may primarily regulate integrin 
specificity for these Ig-like domains. In the case of ICAM-1, 
several residues distinct from the conserved I(L)-D(E)-S(T)- 
P(or S)-L motif are important for LFA-1 binding (52), but 
no residues in VCAM-1 analogous to these in ICAM-1 were 
I(L) - D(E). S(T)- P(X). L(X) ] 
human ICAM-I D1 
human ICAM-2 D1 
human ICAM-3 D1 
human VCAM-I D1 
human VCAM-I D4 
murine ICAM-I D1 
murine ICAM-2 D1 
murine VCAM-I D1 
murine VCAM-I D4 
CSTSCDQPKLLG  .... 
CSTTCNQPEVGG  .... 
CSTDCFSSEKIA  .... 
CSTTGCESPFFSWRTQ 
CSVMGCESPSFSWRTQ 
CSSSCKEDLSLG  .... 












Figure 7. Alignment of residues from human ICAM-1, ICAM-2, 
ICAM-3, and VCAM-1 and murine ICAM-1, ICAMo2,  and VCAMq 
(8, 10, 16, 20, 21, 36, 39, 49, 53, 54, 58, 64). A conserved amino 
acid motif  is boxed. Residues within this motif are proposed to be 
involved in the binding of these domains to integrins. 
found to be important for VLA-4 binding. Similarly, the resi- 
due Q3s in domain 1 of VCAM-1 was required for VLA-4 
binding, but a residue analogous to Q3s is not expressed in 
ICAM-1 (Fig. 5). Most likely there are other nonconserved 
residues of VCAM-1 that confer specificity for binding to 
VLA-4. 
There is good precedence for conserved amino acid motifs 
dictating integrin binding. The motif R-G-D has long been 
recognized as contributing to integrin binding, particularly 
to extraceUular matrix proteins such as fibronectin (51). Nei- 
ther VCAM-1 nor ICAMq includes the R-G-D (or R-G-E) 
motif. Fibronectin binds to VLA-5 via an R-G-D site,  but 
VLA-4 binds to fibronectin via the CS-1 peptide (18, 31, 60). 
The minimal essential sequence for CS-1 binding to VLA-4, 
L-D-V  (25,  61),  is  related to the  I-D-S-P-L  sequence  of 
VCAM-1 in that both express I(L)-D. The tripeptide L-E-V, 
however, does not support VLA-4 binding (25), whereas ei- 
ther an aspartate or glutamate residue is functional in the 
I(L)-D(E)-S(T)-P-L sequence within human VCAM-1 and 
ICAM-1. 
It is not clear how the domain 1-dependent mAb tested 
here blocked VLA-4--dependent adhesion to domain 4 as ex- 
pressed on VCAM-7D, although this phenomenon is clearly 
not the case for all domain 1-dependent mAb that have been 
examined (37).  It has been suggested (37) that certain mAb 
bind to domain 1 on VCAM-7D in such a configuration as 
to hinder domain 4 activity sterically, or, that upon binding 
of these mAb, the conformation of domain 4 is perturbed, 
rendering it incapable of interacting with VLA-4. Another 
explanation would be that these mAb have a high affinity for 
a domain 1 epitope and a low affinity for a domain 4 epitope. 
The 73%  amino acid identity between domains  1 and 4 
favors cross-reactions between them. High-affinity binding 
of one Fab of anti-VCAM-1 IgG to domain 1 would greatly 
increase the local concentration of  the other Fab, favoring its 
binding to domain 4, thus inhibiting domain 4 binding to 
VLA-4. In the absence of domain 1 expression, the affinity 
for domain 4 would ordinarily be too low for mAb binding 
to be detected by flow cytometry. The use of Fab fragments 
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possibilities.  In the present study, one mAb,  HAE-2b,  did 
not bind to VCAM-7D/D1-,  which contained one copy of 
domain 4, but did bind to VC-D4/IgG, which contained two 
copies, perhaps because  bivalent binding of HAE-2b  was 
facilitated. It is also possible that HAE-2b binds VC-D4/IgG 
and  not  VCAM-TD/D1-  because  domains  2  and  3  on 
VCAM-7D/D1-  mask its epitope  in domain 4. 
In summary, we have demonstrated that VLA-4 binds in- 
dependently  to  domains  1  and  4  of VCAM-1, involving 
amino acids within the linear sequence Q-I-D-S-P-L that is 
identically expressed in each domain.  Five of these amino 
acids represent the conserved motif I(L)-D(E)-S(T)-P(or  S)- 
L, also found in human ICAM domains. We propose that this 
conserved motif provides a necessary but insufficient contri- 
bution to each VLA-4-binding site and that additional non- 
conserved  residues confer specificity  for integrin binding. 
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